ArticleWorld journal of gastrointestinal oncology2025
Secular trend in universal hepatocellular carcinoma prevention: Taiwan, Poland, and Belgium experience.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver cancer poses a significant public health threat. The difference between disease patterns and national policies is crucial to elucidating factors influencing hepatocellular carcinoma (HCC) incidence.
aimTo investigate the secular trend and disease pattern of liver cancer in Taiwan, Poland, and Belgium.
methodsThis population-based cohort study presents the incidence, period, and cohort effects in HCC incidence between 2000 and 2019 in Taiwan, Poland, and Flanders, Belgium. Data on HCC were obtained from cancer registry data from Taiwan, Poland, and regional data from Belgium. Age-standardized incidence rates (ASIRs), annual percentage changes, and age-period-cohort analyses were conducted by sex and period.
resultsTaiwan's ASIR decreased from 2000 to 2019 (males: 55.17 to 43.42, females: 21.91 to 16.20, per 100000). In Poland, ASIR declined from 2000 to 2019 (males: 3.21 to 2.77, females: 1.95 to 1.32, per 100000). However, Flanders experienced an increase in ASIR from 2000 to 2019 (males: 2.66 to 5.63, females: 1.40 to 2.20, per 100000). In Taiwan, the cohort effect rate ratio increased from 1915 to 1935 (males: 1.02 to 1.36, females: 1.04 to 1.54) and decreased from 1935 to 1989 (males: 1.36 to 0.22, females: 1.54 to 0.20). In Poland, rate ratios consistently decreased (males: 1.75 to 0.25, females: 3.46 to 0.26). Flanders exhibited an increase in both males (0.14 to 2.52, 1915 to 1975) and females (0.53 to 3.66, 1915 to 1989).
conclusionTaiwan and Poland's declining ASIR may be due to effective hepatitis B virus immunization and viral hepatitis therapy. Flanders' persistent increase may be tied to higher HCC risk in high hepatitis C virus risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.